{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(3)"],"submitter":["Rambaldi A"],"pubmed_abstract":["Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN) characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone marrow, mainly due to a Janus kinase 2 gene mutation (JAK2<sup>V617F</sup>). Givinostat, a histone-deacetylase inhibitor that selectively targets JAK2<sup>V617F</sup> cell growth, has demonstrated good efficacy and safety in three phase 1/2 studies in patients with PV. This manuscript focuses on the 4-year mean (2.8 year median) follow-up of an open-label, long-term study that enrolled 51 patients with PV (out of a total of 54 with MPN) who received clinical benefit from givinostat in these previous studies or on compassionate use, and who continued to receive givinostat at the last effective and tolerated "],"journal":["Blood cancer journal"],"pagination":["53"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7936975"],"repository":["biostudies-literature"],"pubmed_title":["Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program."],"pmcid":["PMC7936975"],"pubmed_authors":["Martinelli V","Guarini A","Bettica P","von Bubnoff N","McMullin MF","Nogai A","De Muro M","Rambaldi A","Iurlo A","Martino B","Manzoni S","Rosti V","Ricco A","Vannucchi AM","Ruggeri M","Luciani S","Di Tollo S"],"additional_accession":[]},"is_claimable":false,"name":"Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.","description":"Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN) characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone marrow, mainly due to a Janus kinase 2 gene mutation (JAK2<sup>V617F</sup>). Givinostat, a histone-deacetylase inhibitor that selectively targets JAK2<sup>V617F</sup> cell growth, has demonstrated good efficacy and safety in three phase 1/2 studies in patients with PV. This manuscript focuses on the 4-year mean (2.8 year median) follow-up of an open-label, long-term study that enrolled 51 patients with PV (out of a total of 54 with MPN) who received clinical benefit from givinostat in these previous studies or on compassionate use, and who continued to receive givinostat at the last effective and tolerated ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-04-29T06:27:02.881Z","creation":"2024-11-13T14:35:10.478Z"},"accession":"S-EPMC7936975","cross_references":{"pubmed":["33677466"],"doi":["10.1038/s41408-021-00445-z"]}}